Drugs / APRINOCARSEN
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00042679 | Jun 2002 → ? | non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00034268 | Mar 2002 → ? | non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2002-05-20 | Ionis Pharmaceuticals | Results New Affinitac(TM) Data in Non-Small Cell Lung Cancer Presented at ASCO ionis.com ↗
The new findings on Affinitac, presented at ASCO on Sunday, May 19, are from ongoing, Phase II clinical trials. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2002-05-20 | Ionis Pharmaceuticals | New Affinitac(TM) Data in Non-Small Cell Lung Cancer Presented at ASCO ionis.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APRINOCARSEN | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108287 ↗ |
| Known as | ISIS 3521 | “A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.” NCT00042679 ↗ |
| Known as | LY900003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00042679 ↗ |
| Known as | Pkc-alpha | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108287 ↗ |
| Modality | Antisense oligonucleotide | “Antisense Nucleotide to PKC-Alpha” NCT00042679 ↗ |
| Target | PRKCA | “Antisense Nucleotide to PKC-Alpha” NCT00042679 ↗ |